Trial Profile

Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 27 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radgocitabine (Primary) ; Azacitidine; Cladribine; Cytarabine; Decitabine; Etoposide; Fludarabine; Idarubicin; Mitoxantrone; Venetoclax
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use
Sponsors Delta-Fly Pharma

22 Jan 2026 Status changed from recruiting to discontinued.
03 Mar 2025 Planned End Date changed from 1 Dec 2022 to 1 Jun 2026.
03 Mar 2025 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com